📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a ß3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB). (2015)

First Author: Rossanese M

Attributed to: MRC Centre for Transplantation funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bju.12730

PubMed Identifier: 24602031

Publication URI: http://europepmc.org/abstract/MED/24602031

Type: Journal Article/Review

Volume: 115

Parent Publication: BJU international

Issue: 1

ISSN: 1464-4096